FDA Designation to Speed Testing of Inhaled Antibiotic, Levofloxacin, to Treat Lung Infections
Bronchiectasis, Cystic Fibrosis, News
Raptor Pharmaceutical Corp. announced that its proprietary inhaled levofloxacin, MP-376, has been given Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) to treat three specific indications: ... Read more